Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Treatment of Multiple Myeloma Patients

New E-Learning module by Prof. San-Miguel is now available. Watch the presentation and take the CME test today!

Learning objectives

  1. To critically elaborate the treatment goals among various settings of patients with multiple myeloma
  2. To provide an update on treatment options for newly diagnosed patients with multiple myeloma
  3. To provide an update on treatment options for patients with relapsed multiple myeloma

The CME test associated with this E-Learning Module has now expired.


Multiple myeloma is a field of intense research efforts which result in changes in standard of care. This E-Learning module is a new edition of the previous ESMO module on the same topic and it provides the most updated overview of results from clinical studies, as well as listing ongoing trials in multiple myeloma.

The author puts an emphasis on finding an appropriate balance among treatment efficacy, toxicity and associated costs as a treatment goal. In that regard, the author elaborates different settings of patients with multiple myeloma and lists the treatment goals for each category.

The author elaborates topics such as: the depth of response correlation to survival outcomes, the minimal residual disease (MRD) as a predictor across multiple myeloma patients’ subgroups, the impact of next-generation flow MRD monitoring, MRD monitoring using NGS, the predictive value of PET/CT after treatment, as well as the International Myeloma Working Group (IMWG) criteria for MRD.

In the second part of the module, the author presents a subset of patients who should not be treated and covers the question about disease control versus curative strategy for high-risk smouldering multiple myeloma.

The author moves from featuring revised IMWG diagnostic criteria for multiple myeloma to cover research efforts in newly diagnosed, transplant-eligible and non-transplant-eligible candidates, as well as to elaborate relapsed settings. These parts of the module are supported by results from recent clinical trials and selected ongoing studies.

In this E-Learning module, the author covers many drugs currently under development and their future outlook. By pointing out that multiple myeloma is a model for scientific and clinical progress from biology to therapeutics, the author concludes that a progress in understanding multiple myeloma cell biology and the discovery of new drugs will lead to individualised and tailored treatment options.

This E-Learning module was published in 2019 and expired in 2022.

Last update: 26 Nov 2019

The author has reported:

 Consultant role: Takeda, Janssen, Celgene, Novartis, Sanofi

Honoraria from Takeda, Janssen, Celgene, Novartis, Amgen, BMS, Sanofi, GlaxoSmithKline, Karyopharm.

Scientific Advisory Role: Takeda, Janssen, Celgene, Novartis, Amgen, BMS, Sanofi, GlaxoSmithKline, Karyopharm.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.